Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05338749 · ClinicalTrials.gov registry record · NA

Computer Cognitive Training for Post-acute COVID-19 Syndrome

A NA study of Cognitive Dysfunction and Corona Virus Infection, sponsored by Nova Southeastern University.

Completed
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT05338749 is a NA study of Cognitive Dysfunction and Corona Virus Infection that has completed, run by Nova Southeastern University. The registered enrollment target is 16 participants, below the 1,993-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05338749, a NA study of Cognitive Dysfunction and Corona Virus Infection, has completed, sponsored by Nova Southeastern University.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This study will assess the acceptability, feasibility, and impact of game-based computer-delivered cognitive training on cognitive function in persons with cognitive symptoms that persist after recovery from acute coronavirus-19 (COVID) infection.

Interventions

  • BEHAVIORAL Cognitive Training

Study Locations (1)

Florida

  • Center for Collaborative Research, Nova Southeastern University - Fort Lauderdale

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2022-04-26
Est. Completion 2023-11-30
Phase NA

Sponsor

Nova Southeastern University

71 total trials

What the Registry Record Tells You About NCT05338749

The ClinicalTrials.gov registry entry for NCT05338749 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,993-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The listed sponsor is Nova Southeastern University, which has 71 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Training is the first listed.

NCT05338749 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05338749 about?

NCT05338749 is a clinical study titled "Computer Cognitive Training for Post-acute COVID-19 Syndrome". This study will assess the acceptability, feasibility, and impact of game-based computer-delivered cognitive training on cognitive function in persons with cognitive symptoms that persist after recovery from acute coronavirus-19 (COVID) infection.

What is the current status of trial NCT05338749?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2022-04-26. Estimated completion is 2023-11-30.

What conditions does trial NCT05338749 study?

This clinical trial studies the following conditions: Cognitive Dysfunction, Corona Virus Infection.

What interventions are being tested in trial NCT05338749?

The interventions under investigation include: Cognitive Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT05338749?

This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05338749 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.